Pauline Londeix (born in 1986) is a French activist[1][2][3][4][5] researcher and writer,[6] who has been particularly involved in the fight for the access to generic medicines used against HIV[7] and Hepatitis C virus (HCV), in particular through contributing to challenging monopolies and intellectual property barriers in the Global South, but also in high income countries, such as France. In 2008, she was the Vice President of the French HIV/AIDS organisation Act Up-Paris.[8][9] In 2011, she co-founded Act Up-Basel.[10]
Background
editShe has been involved in the fight against HIV/AIDS since 2005. In 2009, she took part to a cross interview with Françoise Barré-Sinoussi in the French daily paper Libération.[11] Since 2011, she has been particularly involved in the access to new hepatitis C breakthrough treatments : the direct acting antivirals. She is the main author [12][13][14] of the Medecins du Monde's report "New treatments for hepatitis C virus : strategies for achieving universal access" (2014) [15][16] that was presented during the International aids conference that took place in Melbourne.[17] She is the author or the co-author of various articles and reports linked to access to medicines.[18][19][20][21]
See also
editReferences
edit- ^ "Accès aux génériques: l'opération coup de poing d'Act-Up chez Novartis". Les Inrocks (in French). Retrieved 2018-02-05.
- ^ ""Les associations passent-elles à côté d'une question cruciale: le coût et la pérennité des soins?" par Pauline Londeix". Yagg (in French). 2012-12-01. Retrieved 2018-02-06.
- ^ ""Le problème du prix des médicaments dans notre société est systémique" (2/2) | Seronet". www.seronet.info (in French). 11 September 2014. Retrieved 2018-02-06.
- ^ "Supply and demand: Why drug prices and rade barriers are blocking drug access and what activists can do about it" (PDF). aidsalliance.org. Retrieved February 6, 2018.
- ^ "Sommet Europe-Inde: "Le risque est d'entraver la production indienne de médicaments à prix abordables"".
- ^ "Foreign rights L'Altiplano : The Lesbian Manifesto". www.laltiplano.fr. Retrieved 2018-02-05.
- ^ "Sommet Europe-Inde: "Le risque est d'entraver la production indienne de médicaments à prix abordables"".
- ^ "Priorité santé - Act-up aujourd'hui". RFI (in French). 2017-08-29. Retrieved 2018-02-06.
- ^ Vice-President (2008) http://www.regards.fr/acces-payant/archives-web/une-nouvelle-equipe-pour-act-up,3086
- ^ "Quand les malades investissent les rues de Bâle — Vacarme". www.vacarme.org.
- ^ "Avec moins de 1 % de l'argent investi pour sauver les banques, il n'y aurait aucun souci". Libération.fr (in French). Retrieved 2018-02-05.
- ^ Boseley, Sarah (17 March 2014). "New hepatitis C drugs must be affordable worldwide, say campaigners". the Guardian.
- ^ "Hépatite C: Peut-on soigner à n'importe quel prix?".
- ^ "Indian public opposition to Hepatitis C medicine patent claim".
- ^ "Inégalités face à l'hépatite C". Le Monde. 17 March 2014.
- ^ "Hépatite C : Bataille pour l'accès à un traitement révolutionnaire". Le Monde. 22 January 2015.
- ^ International AIDS Conference (2014-07-28), HCV drug pricing, retrieved 2018-02-05
- ^ "AIDS Today: 2014 edition - International HIV/AIDS Alliance". Archived from the original on 2018-10-10. Retrieved 2018-02-05.
- ^ "Access to hepatitis C medicines". World Health Organization. Archived from the original on December 5, 2015. Retrieved 2018-02-05.
- ^ "Pauline Londeix, ACCESS (English Translation)". High-Level Panel on Access to Medicines. Retrieved 2018-02-05.
- ^ Ford, Nathan; Wiktor, Stefan; Kaplan, Karyn; Andrieux-Meyer, Isabelle; Hill, Andrew; Radhakrishnan, Priti; Londeix, Pauline; Forette, Chloe; Momenghalibaf, Azzi (2015-11-01). "Ten priorities for expanding access to HCV treatment for people who inject drugs in low- and middle-income countries". International Journal of Drug Policy. 26 (11): 1088–1093. doi:10.1016/j.drugpo.2015.05.004. ISSN 0955-3959. PMID 26074094.